The United States Food and Drug Administration has approved Freenome’s SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 and older. Abbott Laboratories will exclusively commercialize the test in the United States beginning in fall 2026, while the approval triggers a $100 million milestone payment to Freenome under the companies’ commercial agreement. The decision adds another blood-based screening option for people who may avoid colonoscopy or stool collection, but the test’s limited detection of advanced precancerous lesions means it should be viewed primarily as a tool for expanding screening participation rather than replacing more preventive screening methods.
How the SimpleScreen CRC blood test fits into colorectal cancer screening
SimpleScreen CRC is intended for asymptomatic adults aged 45 and older who are considered at average risk for colorectal cancer and have been referred for screening by a healthcare provider. The test is not indicated for people with a personal history of colorectal cancer or advanced precancerous lesions, certain hereditary cancer syndromes, inflammatory bowel disease or specified high-risk family histories. A positive result must be followed by colonoscopy, while the blood test cannot replace diagnostic colonoscopy or surveillance colonoscopy for high-risk patients.
The test uses two tubes of blood and analyzes cell-free DNA extracted from plasma. Freenome’s laboratory applies a machine-learning-enabled classifier to identify DNA methylation patterns associated with colorectal cancer and certain advanced precancerous lesions. Samples are sent to Freenome’s Clinical Laboratory Improvement Amendments-certified laboratory, with results expected in approximately two weeks.
The attraction is convenience. Colonoscopy requires bowel preparation, time away from work or normal activities and, in many cases, sedation and transportation support. Stool-based screening avoids an invasive procedure but requires patients to collect and return a sample. A blood draw can be incorporated more easily into routine medical care, potentially reaching people who remain unscreened because they are unwilling to complete another available method.
That convenience does not make SimpleScreen CRC the preferred option for every patient. The American Cancer Society’s 2026 guideline includes blood-based tests among recommended colorectal cancer screening choices, but continues to prefer visual examinations and stool-based methods because blood tests are less effective at detecting precancerous growths and Stage 1 disease. The organization emphasizes that a positive blood or stool result requires timely follow-up colonoscopy to complete the screening process.
The practical value of SimpleScreen CRC will therefore depend partly on whom it reaches. A less sensitive test that is completed may benefit a person who would otherwise remain entirely unscreened. The same test may offer less preventive value than colonoscopy or a higher-performing stool-based method for someone willing and able to complete those options.
What the PREEMPT CRC study showed about cancer and precancer detection
The FDA approval was supported by the PREEMPT CRC study, a prospective clinical validation program conducted at more than 200 sites. The study enrolled 48,995 asymptomatic adults aged 45 to 85 who were at average risk and scheduled for screening colonoscopy, with 27,010 participants included in the primary published evaluation after application of the prespecified study cutoff.
In an analysis adjusted to reflect the age and sex distribution of the 2020 United States Census population, SimpleScreen CRC demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. In practical terms, the test detected approximately eight in 10 cancers and correctly returned a negative result for roughly nine in 10 people who did not have colorectal cancer or an advanced precancerous lesion.
The limitation is precancer detection. The approved version identified 13.7% of advanced precancerous lesions overall and 30.5% of advanced precancerous lesions containing high-grade dysplasia. Those figures matter because colorectal cancer screening is not only intended to find established cancer. Colonoscopy can prevent cancer by locating and removing precancerous polyps before malignant transformation occurs.
SimpleScreen CRC’s performance therefore supports its use as a cancer-detection option, but provides a weaker prevention proposition than methods with greater precancer sensitivity. A negative blood result does not establish that a patient has no precancerous lesion, and patients must continue screening at the recommended interval rather than interpreting one negative result as long-term protection.
Specificity also influences how many people without advanced disease are sent for colonoscopy. At 90.4% specificity, some screened individuals will receive positive results despite having neither colorectal cancer nor an advanced precancerous lesion. That is expected with population screening, but it reinforces the need for clear counselling about what a positive result means and why colonoscopy is required before a diagnosis can be made.
Why the approved SimpleScreen CRC test differs from Freenome’s updated assay
The FDA approval covers the first-generation SimpleScreen CRC version submitted through Freenome’s premarket approval application in August 2025. Freenome separately reported results in July 2026 from an updated assay and algorithm intended to improve detection of advanced precancerous lesions. The updated version has not received FDA approval and will require a supplemental premarket approval submission before it can replace or expand upon the newly approved test.
In the updated validation analysis, the next-generation version produced 80.4% colorectal cancer sensitivity, 18.2% sensitivity for advanced precancerous lesions and 41.9% sensitivity for advanced precancerous lesions with high-grade dysplasia, with 90% specificity among participants without colonoscopy findings. The improvement was most visible in precancer detection, although the figures still show that most advanced precancerous lesions were not identified through the blood test.
Keeping the two versions separate is important. The stronger high-grade dysplasia performance reported in July should not be presented as part of the current FDA-approved label unless the agency later authorizes the updated assay. Abbott’s initial commercial launch will be based on the approved version and its established PREEMPT CRC performance.
The supplemental development strategy may eventually strengthen the product’s clinical position. Improved precancer sensitivity could make the test more competitive with other noninvasive methods and increase its ability to contribute to cancer prevention rather than detection alone. The timing, regulatory review and final labeling of that updated version remain uncertain.
How Medicare coverage and Abbott commercialization could affect patient access
SimpleScreen CRC’s 81.1% colorectal cancer sensitivity and 90.4% specificity exceed the minimum performance thresholds historically established by the Centers for Medicare and Medicaid Services for covered blood-based colorectal cancer screening tests. The national coverage framework requires FDA authorization, colorectal cancer sensitivity of at least 74% and specificity of at least 90%, together with other patient and laboratory conditions.
Meeting the performance threshold creates an important reimbursement pathway, although practical coverage will still depend on applicable Medicare rules, coding, laboratory processes and implementation. Private insurers may make separate coverage decisions, while patient cost-sharing and provider workflow could influence adoption.
Abbott Laboratories brings national commercial infrastructure, provider relationships, reimbursement capabilities and patient-support experience to the launch. The company plans to make SimpleScreen CRC available in the United States during fall 2026, while Freenome will continue operating the laboratory and developing future generations of the test. The approval milestone also provides Freenome with $100 million under the commercial agreement, giving the company additional resources as it transitions from research and development into commercial diagnostics.
The partnership could accelerate adoption because colorectal cancer screening depends on more than regulatory approval. Physicians must understand which patients are eligible, laboratories must process samples reliably, positive patients must complete colonoscopy and insurers must reimburse the test. Abbott’s scale could help integrate SimpleScreen CRC into health systems and routine primary-care workflows more quickly than Freenome could achieve alone.
Commercial reach will not resolve the follow-up challenge. A blood screening program produces its intended benefit only when patients with positive results undergo timely colonoscopy. Delayed or incomplete follow-up can undermine early detection, while people who are unwilling to undergo colonoscopy after a positive blood test may not complete the screening process.
How SimpleScreen CRC compares with the expanding blood-based screening market
SimpleScreen CRC becomes another FDA-approved blood-based colorectal cancer screening option after Guardant Health’s Shield test. Shield is also approved for average-risk adults aged 45 and older and similarly requires colonoscopy after a positive result. The emergence of competing blood tests confirms that colorectal cancer screening is expanding beyond the historical choice between colonoscopy and stool collection.
Competition will involve more than headline cancer sensitivity. Health systems will compare specificity, Stage 1 detection, precancer sensitivity, test frequency, price, laboratory turnaround, insurance coverage and the percentage of positive patients who complete colonoscopy. Abbott’s commercial scale may become a significant advantage, while Freenome’s planned assay improvements could strengthen future performance.
Freenome shares were trading near $11.51 during the July 27 session, up approximately 2.4% from the previous close after reaching an intraday high of $12.74. Abbott Laboratories shares were trading near $104.92, up approximately 1.8%. Freenome’s larger intraday range suggests investors were actively reassessing the value of its first approved commercial product and the $100 million milestone, while the approval represents a smaller financial event within Abbott’s much larger diagnostics and healthcare portfolio.
The clinical significance of SimpleScreen CRC lies in giving physicians another way to reach people who are not completing established screening. Its commercial significance lies in combining Freenome’s molecular testing platform with Abbott’s ability to scale access. The unresolved issue is whether easier screening will bring enough previously unscreened adults into care to outweigh the test’s limited ability to find precancerous lesions.
SimpleScreen CRC should therefore be positioned as an additional route into colorectal cancer screening rather than a universal replacement for colonoscopy or stool-based testing. Its greatest public-health contribution may come from patients who would otherwise receive no screening at all, provided positive results lead promptly to diagnostic colonoscopy.
